Nanotechnology Now - Press Release: U.S. Government Researchers Validate High Energy Capability of Nanoparticles, Key to Octillion’s NanoPower Windows

Home > Press > U.S. Government Researchers Validate High Energy Capability of Nanoparticles, Key to Octillion’s NanoPower Windows

Abstract:
Silicon nanoparticles show high-energy effect capable of converting more of the sun's energy to electricity in Department of Energy study; Power performance of solar cells boosted by 60-70% in separate study of nanoparticles used in Octillion's NanoPower Windows.

U.S. Government Researchers Validate High Energy Capability of Nanoparticles, Key to Octillion’s NanoPower Windows

Vancouver, Canada | Posted on August 21st, 2007

Octillion Corp. (OTCBB:OCTL) today announced that researchers at the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) have observed a new and important high-energy effect in silicon nanoparticles - the principal material used in Octillion's NanoPower Window technology - which results in a process where more of the sun's energy is converted into electricity.

"This third-party research by NREL validates our long-held belief that silicon nanoparticles have the ability to generate significant energy from sunlight," explained Mr. Harmel S. Rayat, President and CEO of Octillion Corp. "These research findings also support our recent decision to accelerate development and double our research funding following encouraging outcomes and completion of our developmental prototype window, a major breakthrough milestone."

Octillion is developing the first-of-its-kind transparent glass window capable of generating electricity using silicon nanoparticles. Last week, in a published study unrelated to the NREL findings, researchers reported that the nanoparticles used in Octillion's NanoPower Window technology are able to substantially increase the power performance of conventional solar cells by 60-70% in the ultraviolet-blue range and significantly boost power by as much as 10% in the visible light range.

In separate research published in the most cited source for nanoscience and nanotechnology (American Chemical Society's Nano Letters Journal; July 24, 2007), NREL scientists reported that silicon nanocrystals can produce more than one electron from single photons of sunlight, a phenomenon referred to as Multiple Exciton Generation (MEG). When today's conventional photovoltaic solar cells absorb a photon of sunlight, about 50 percent of the incident energy is lost as heat. MEG provides a way to convert some of this energy lost as heat into additional electricity.

Importantly, the silicon nanoparticles used in Octillion's NanoPower Window technology are able to successfully convert the same UV components that typically cause damage and create wasteful heat into useful electrical energy, a recently published finding. (American Institute of Physics' Applied Physics Letters; August 6, 2007)

According to the NREL, until now MEG has only been reported to occur in: nanocrystals made of materials not currently used in commercial solar cells; and generally unsafe materials such as lead. In contrast, Octillion's high-energy nanoparticles are made of silicon, a toxicologically inert substance and the world's most abundant, naturally-occurring element, second only to oxygen. Octillion's NanoPower Window technology exclusively makes use of nanoparticles from silicon.

####

About Octillion Corp.
Octillion Corp. is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging solar energy and solar related technologies.

Among our current research and development activities is the development of a patent-pending technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure.

The technological potential of adapting existing glass windows into ones capable of generating electricity from the sun’s solar energy has been made possible through a ground breaking discovery of an electrochemical and ultrasound process that produces identically sized (1 to 4 nanometers in diameter) highly luminescent nanoparticles of silicon that provide varying wavelengths of photoluminescence with high quantum down conversion efficiency of short wavelengths (50% to 60%).

When thin films of silicon nanoparticles are deposited (sprayed) onto silicon substrates, ultraviolet light is absorbed and converted into electrical current. With appropriate connections, the film acts as nanosilicon photovoltaic solar cells that convert solar radiation to electrical energy.

The process of producing silicon nanoparticles is supported by 10 issued US patents, 7 pending US patents, 2 issued foreign counterpart patents and 19 pending foreign counterpart patents.

For additional information regarding Octillion Corp., please visit http://www.octillioncorp.com or call toll free 800-213-0689 to speak to a shareholder representative.

To receive future press releases via email, please visit:

http://www.octillioncorp.com/contact.html .

To view the full HTML text of this release, please visit:

http://www.octillioncorp.com/OCTL_20070821.html .

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Octillion Corp. (the “Company” or “Octillion”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Octillion will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov . The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.